- Home
- EVM vs INBX Comparison
EVM vs INBX Comparison
Compare EVM & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVM
- INBX
- Stock Information
- Founded
- EVM 2002
- INBX 2010
- Country
- EVM United States
- INBX United States
- Employees
- EVM N/A
- INBX N/A
- Industry
- EVM Finance/Investors Services
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- EVM Finance
- INBX Health Care
- Exchange
- EVM Nasdaq
- INBX Nasdaq
- Market Cap
- EVM 228.0M
- INBX 190.2M
- IPO Year
- EVM N/A
- INBX 2020
- Fundamental
- Price
- EVM $9.36
- INBX $12.56
- Analyst Decision
- EVM
- INBX Hold
- Analyst Count
- EVM 0
- INBX 1
- Target Price
- EVM N/A
- INBX N/A
- AVG Volume (30 Days)
- EVM 55.8K
- INBX 88.8K
- Earning Date
- EVM 01-01-0001
- INBX 11-14-2024
- Dividend Yield
- EVM 4.01%
- INBX 6.77%
- EPS Growth
- EVM N/A
- INBX N/A
- EPS
- EVM 0.20
- INBX 119.38
- Revenue
- EVM N/A
- INBX $1,568,000.00
- Revenue This Year
- EVM N/A
- INBX N/A
- Revenue Next Year
- EVM N/A
- INBX N/A
- P/E Ratio
- EVM $47.61
- INBX $0.11
- Revenue Growth
- EVM N/A
- INBX 19.24
- 52 Week Low
- EVM $7.67
- INBX $10.80
- 52 Week High
- EVM $9.59
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- EVM 48.24
- INBX 42.38
- Support Level
- EVM $9.28
- INBX $12.08
- Resistance Level
- EVM $9.39
- INBX $13.60
- Average True Range (ATR)
- EVM 0.06
- INBX 0.76
- MACD
- EVM -0.01
- INBX 0.05
- Stochastic Oscillator
- EVM 33.33
- INBX 20.87
About EVM Eaton Vance California Municipal Bond Fund of Beneficial Interest $.01 par value
Eaton Vance California Municipal Bond Fund is an investment company with an objective to provide current income exempt from regular federal income tax, including alternative minimum tax, and, in state specific funds, taxes in its specified state. The company provides its solutions to individual investors, institutional investors, high net worth individuals, family office investors, and financial professionals. It offers a range of equity, income, and alternative strategies to institutional investors, both in the United States and internationally.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.